Amendment to Schedule 13D Filing for LakeShore Biopharma Co., Ltd

This filing is an amendment to a previous Schedule 13D, originally filed on July 22, 2025. The amendment, dated March 24, 2026, concerns the proposed merger between Oceanpine Skyline Inc. (Parent) and Oceanpine Merger Sub Inc. (Merger Sub) with LakeShore Biopharma Co., Ltd (the Issuer). The key change is a revised non-binding proposal from Parent and Merger Sub to acquire all outstanding ordinary shares of the Issuer at US$0.06 per share, a significant reduction from the previous US$0.90 per share. This price adjustment is attributed to the substantial monetary liabilities (approximately RMB576.5 million) arising from arbitral awards, which are deemed to have a material adverse effect on the Issuer's financial condition. The revised proposal acknowledges the risks associated with these awards but expresses continued commitment to the transaction to provide value to unaffiliated shareholders. If consummated, the transaction would result in the delisting of the Issuer's shares from OTC Markets and its transition to a privately held company. The source of funds remains equity capital arranged by the Reporting Persons, with existing shareholders anticipated to roll over their equity interests. The filing also includes a Joint Filing Agreement among the Reporting Persons, dated March 25, 2026.